Halfon, Philippe <br/><br/>
Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).  [electronic resource] 

 -  Journal of medical virology  Dec 2010 
 - 2027-31 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-9071 
<br/><br/><label>Standard No.: </label>10.1002/jmv.21909  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Neutralizing--blood<br/>Antiviral Agents--pharmacology<br/>Drug Therapy, Combination<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--blood<br/>Interferon-gamma--therapeutic use<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--pharmacology<br/>RNA, Viral--blood<br/>Recombinant Proteins<br/>Ribavirin--pharmacology<br/>Treatment Failure<br/>Treatment Outcome<br/>Viral Load<br/>Young Adult